Seniors

Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo

Black Health & Social Services Hub to Celebrate Grand Opening with Community Health, Culture and Wellness Celebration in Brampton

Brampton, Ontario--(Newsfile Corp. - August 27, 2026) - The Black Health and Social Services (BHSS) Hub Peel will officially celebrate...

The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon

SHELTON, CT / ACCESS Newswire / August 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...

Dr. Oz’s Push to Expand Medicare CBD Access After European Regulators Could Not Establish Safety of Charlotte’s Web Hemp Extract

"Medicare patients should not become the testing ground for cannabinoid products that have not undergone the rigorous FDA drug development...

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

Something Is Rotten at CMS: Dr. Oz Demands FDA Approval – Then Defends a $500 Medicare Pathway for Unapproved Hemp Products

"Approaching FDA for Formal Approval Is the Right Way to Move Forward" with Cannabinoid Drug Development" stated Dr. Oz. "However...

NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial

George E. Norcross III to Donate $100 Million to Cooper University Health Care/MD Anderson Cancer Center at Cooper in Honor of His Parents, George E. Norcross Jr. and Anne Carol Conner Norcross

error: Content is protected !!